ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 0740 • ACR Convergence 2023

    Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease

    Shivani Garg1, Brad Astor2, S. Sam Lim3, Amish Raval2, Weixiong Zhong2, Sarah Panzer2, Brad Rovin4 and Christie M. Bartels2, 1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 2University of Wisconsin, School of Medicine and Public Health, Madison, WI, 3Emory University, Atlanta, GA, 4Ohio State University, Columbus, OH

    Background/Purpose: Patients < 40 years old with lupus nephritis (LN) face 42-fold higher risk of cardiovascular disease (CVD) compared to peers. Traditional CVD risk calculators…
  • Abstract Number: 0920 • ACR Convergence 2023

    Proinflammatory Neutrophils and NETs Mediate Skin and Kidney Inflammation During Lupus Flare in Asymptomatic Lupus-prone Mice Triggered by UVB

    Xing Lyu1, minghui li1, ping zhang2, Wei Wei3, victoria werth4 and Ming-Lin Liu5, 1Tianjin Medical University, Tianjin, China, 2Beaumont Hospital Royal Oak, Royal Oak, MI, 3Tianjin Medical University General Hospital, Tianjin, China, 4University of Pennsylvania, Wynnewood, PA, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Ultraviolet B (UVB) exposure triggers lupus flare by worsening both skin lesions and systemic symptoms, i.e. lupus nephritis. We recently reported that UVB exposure…
  • Abstract Number: 1481 • ACR Convergence 2023

    Racial Disparities in Lupus Nephritis: A Nationwide Analysis

    Faria Sami1, Shahzad Ahmed Sami2, Augustine Manadan3 and Shilpa Arora1, 1John H. Stroger Jr. Hospital of Cook County, Chicago, IL, 2Trinity Health Oakland Hospital, Chicago, IL, 3Rush University Medical Center, Chicago, IL

    Background/Purpose: Lupus nephritis (LN) is a significant predictor of morbidity and mortality in Systemic Lupus Erythematosus (SLE). Racial disparities are known to exist in SLE…
  • Abstract Number: 1652 • ACR Convergence 2023

    Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders

    Melicent Miller1, Stephanie Slan1, Rosalind Ramsey-Goldman2, Rodlescia Sneed3, Candace Feldman4, Patrick Wildman1, Tori Justin5, Lydia Oberholtzer5 and Joy Buie6, 1Lupus Foundation of America, Washington, DC, 2Northwestern University, Chicago, IL, 3Wayne State University, Detroit, MI, 4Brigham and Women's Hospital, Boston, MA, 5Sharp Insight, LLC, Montgomery County, MD, 6Lupus Foundation of America, York, SC

    Background/Purpose: Black/African American people with lupus (PWL) experience greater disease prevalence and severity than White PWL. The need for more racial and ethnic diversity amongst…
  • Abstract Number: 2336 • ACR Convergence 2023

    Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis

    David Jayne1, Eduardo Mysler2, Zahir Amoura3, Patrick Gavin4, Erik Allman4, Cristina Di Poto4, Xiang Tian4, Sonja Hess4, Eszter Csomor5, Philip Brohawn4, Daniel Muthas5, Adam Platt6, Hussein Al-Mossawi6, Catharina Lindholm5 and Nicola Ferrari6, 1University of Cambridge, Cambridge, United Kingdom, 2Organizacion Medica de Investigacion, Buenos Aires, Argentina, 3French National Reference Center for SLE, Hôpital La Pitié-Salpêtrière, Paris, France, 4BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 5BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 6BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: LN is a severe complication of SLE, affecting 21%–48% of patients.1 Development of noninvasive diagnostic tests for LN is ongoing; urinary biomarkers have good…
  • Abstract Number: 0781 • ACR Convergence 2023

    Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials

    Amit Saxena1, Peter Izmirly2, Jammie Law3, Cristina Sorrento3, H Michael Belmont4 and Jill Buyon5, 1New York University Grossman School of Medicine, Rheumatology, New York, NY, 2New York University School of Medicine, New York, NY, 3New York University, New York, NY, 4NYU School of Medicine, New York, NY, 5NYU Grossman School of Medicine, New York, NY

    Background/Purpose: Traditional induction treatment regimens for proliferative or membranous lupus nephritis (LN) have utilized oral glucocorticoids (GC) in initial doses up to 1.0 mg/kg/day prednisone…
  • Abstract Number: 0921 • ACR Convergence 2023

    SAPhigh T Peripheral Helper Cells Are a Novel Subset Associated with Lupus Nephritis

    Yevgeniya Gartshteyn1, Leila Khalili2, Laura Geraldino-Pardilla2, Adam Mor3 and Anca Askanase4, 1Columbia University Medical Center, New York, NJ, 2Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, 3Columbia University, New York, NY, 4Columbia University Medical Center, New York, NY

    Background/Purpose: Better understanding of the abnormal immune responses in lupus nephritis (LN) is fundamental to identifying new therapies. We previously reported that the adaptor protein…
  • Abstract Number: 1482 • ACR Convergence 2023

    Change in the SLE Mortality Rate and Prevalence of Lupus Nephritis Overtime: Single Center Retrospective Study in Japan

    Takehiro Nakai1, Sho Fukui2, Takahiro Asano1, Futoshi Iwata1, Hiroki Ozawa3, Satoshi Kawaai1, Yukihiko Ikeda4, Haruyuki Yanaoka1, Hiromichi Tamaki1, Mitsumasa Kishimoto5, Kenichi YAMAGUCHI6 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2Brigham and Women's Hospital, Boston, MA, 3Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, 4St Luke's international hospital in Japan, Tokyo, Japan, 5Kyorin University School of Medicine, Yokohoma, Japan, 6St.Luke's International Hospital, Tokyo, Japan

    Background/Purpose: Over the past several decades, the treatment of lupus has seen significant advancements, with the approval of belimumab in 2017, and anifrolumab in 2021.…
  • Abstract Number: 1693 • ACR Convergence 2023

    Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures

    Alice Horisberger1, Alec Griffith1, Arnon Arazi2, Joshua Keegan1, Kaitlyn Howard1, Takanori Sasaki1, Tusharkanti Ghosh3, Andrea Fava4, Jun Inamo5, John Pulford1, Ekaterina Murzin1, Brandon Hancock1, Katie Preisinger6, Maria Gutierrez-Arcelus7, Thomas Eisenhaure8, Joel Guthridge9, Paul Hoover10, Maria Dall'Era11, David Wofsy11, Diane L. Kamen12, Kenneth Kalunian13, Richard Furie14, H Michael Belmont15, Peter Izmirly6, Robert Clancy16, David Hildeman17, steve Woodle17, William Apruzzese18, Maureen McMahon19, Jennifer Grossman20, Jennifer Barnas21, Fernanda Payan-Schober22, Mariko Ishimori23, Accelerating Medicines Partnership Program RA SLE Network23, Matthias Kretzler24, Celine Berthier24, Jeff Hodgin24, Dawit Demeke24, Chaim Putterman25, Nir Hacohen8, Michael Brenner1, Jennifer Anolik21, Anne Davidson26, Judith James9, Soumya Raychaudhuri10, Michelle Petri27, Jill Buyon16, Betty Diamond26, The Accelerating Medicines Partnership In RA/SLE28, Fan Zhang29, James Lederer1 and Deepak Rao10, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Broad Institute of MIT and Harvard, Melrose, MA, 3School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, 4Johns Hopkins University, Baltimore, MD, 5University of Colorado School of Medicine, Aurora, CO, 6New York University School of Medicine, New York, NY, 7Boston Children's Hospital, Boston, MA, 8Broad Institute of MIT and Harvard, Cambridge, MA, 9Oklahoma Medical Research Foundation, Oklahoma City, OK, 10Brigham and Women's Hospital, Boston, MA, 11University of California San Francisco, San Francisco, CA, 12Medical University of South Carolina, Charleston, SC, 13University of California San Diego, La Jolla, CA, 14Northwell Health, Manhasset, NY, 15NYU School of Medicine, New York, NY, 16NYU Grossman School of Medicine, New York, NY, 17University of Cincinnati College of Medicine, Cincinnati, OH, 18Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, 19UCLA David Geffen School of Medicine, Los Angeles, CA, 20University of California Los Angeles, Los Angeles, CA, 21University of Rochester Medical Center, Rochester, NY, 22Texas Tech University Health Sciences Center, El Paso, TX, 23Cedars-Sinai Medical Center, Los Angeles, CA, 24University of Michigan, Ann Arbor, MI, 25Albert Einstein College of Medicine, Bronx, NY, 26Feinstein Institutes for Medical Research, Manhasset, NY, 27Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 28multisites, multisites, 29University of Colorado, Aurora, CO

    Background/Purpose: Patients with lupus nephritis (LN) have variable responses to standard-of-care therapy, and a third of patients with class III, IV, or V show a…
  • Abstract Number: 2338 • ACR Convergence 2023

    Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis

    Maria Dall'Era1, Juan Lichauco2, Hsiang Chen3, Harold Gomez4, Michael Tee5, Caroline Arroyo6, Joung-Liang Lan7, Yao-Fan Fang8, Edmund Chang9, Noosha Yousefpour9, Julian Low9, Min Bao9, Qing Chang9, Jeannette Osterloh9, Ann Mongan9, Ted Yednock9, Dean Artis9, Yaisa Andrews-Zwilling9 and Henk-Andre Kroon9, 1University of California San Francisco, San Francisco, CA, 2St. Luke’s Medical Center, Quezon City, Philippines, 3Tri-service General Hospital, Taipei City, Taiwan, 4Angeles University Foundation Medical Center, Pampanga, Philippines, 5Medical Center Manila and University of the Philippines Manila, Manila, Philippines, 6Iloilo Doctors Hospital, Iloilo City, Philippines, 7China Medical University Hospital, Taichung, Taiwan, 8Chang Gung Memorial Hospital, Linkou, Taiwan, 9Annexon Biosciences, Brisbane, CA

    Background/Purpose: Lupus nephritis (LN) is an autoantibody-mediated disease involving glomerular deposition of immune complexes containing pathogenic anti-C1q antibodies, leading to C1q binding and activation of…
  • Abstract Number: 047 • 2023 Pediatric Rheumatology Symposium

    Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide

    Christine Wang1, Rebecca Sadun2, Wenru Zhou3, Kristen Miller3, Claire Palmer3, Stacy Ardoin4, Christine Bacha5, Emily Hause6, Joyce Hui-Yuen7, Nicole Ling8, Maria Pereira9, Meredith Riebschleger1, Kelly Rouster-Stevens10, Aliese Sarkissian11, Julia Shalen12, William Soulsby13, Marinka Twilt14, Eveline Wu15, Laura Lewandowski16, Scott Wenderfer17 and Jennifer Cooper18, 1University of Michigan, Ann Arbor, MI, 2Duke University, Durham, NC, 3University of Colorado, Denver, CO, 4Nationwide Children's Hospital, Columbus, OH, 5Akron Children's Hospital, Akron, OH, 6University of Minnesota, Minneapolis, MN, 7Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, 8UCSF, San Francisco, CA, 9Baylor College of Medicine, Houston, TX, 10Emory University/Children's Healthcare of Atlanta, Atlanta, GA, 11UNC- Chapel Hill, Durham, NC, 12Johns Hopkins University, Baltimore, MD, 13University of California, San Francisco, San Francisco, CA, 14Alberta Children's Hospital, Calgary, AB, Canada, 15UNC Chapel Hill, Chapel Hill, NC, 16NIAMS, NIH, Bethesda, MD, 17British Columbia Children's Hospital, Vancouver, BC, Canada, 18University of Colorado/Children's Hospital Colorado, Denver, CO

    Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
  • Abstract Number: 050 • 2023 Pediatric Rheumatology Symposium

    Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort

    Sara Patrizi1, Megha Tandel2, Derek Boothroyd2 and Joyce Hsu1, 1Stanford Medicine, Children's Health, Palo Alto, CA, 2Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: In 2019, new classification criteria for SLE were developed by the EULAR/ACR. Prior research in adult lupus cohorts found a positive correlation between high…
  • Abstract Number: 005 • 2023 Pediatric Rheumatology Symposium

    Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study

    Emily Zhang1, Gabrielle Alonzi1, Madeline Hlobik1, Esra Meidan1, Mindy Lo1, Olha Halyabar2, Melissa Hazen1, Ezra Cohen3, Lauren Henderson1, Siobhan Case4, Margaret Chang1, Camille Frank1, Ankana Daga1, Jonathan Hausmann5, Ahmad Bakhsh1, Liyoung Kim1, Daniel Ibanez1, Holly Wobma1, Mia Chandler6, Fatma Dedeoglu1, Robert Sundel1, Peter Nigrovic1, Karen Costenbader7, Mary Beth Son1 and Joyce Chang1, 1Boston Children's Hospital, Boston, MA, 2Children's Hospital/Boston Medical Center, Boston, MA, 3Boston Medical Center, Boston, MA, 4Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, 5Boston Children's Hospital / Massachusetts General Hospital, Boston, MA, 6Boston Children's Hospital; Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital/ Harvard Medical School, Boston, MA

    Background/Purpose: The morbidity of chronic glucocorticoid (GC) use is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The newly developed pediatric glucocorticoid…
  • Abstract Number: 012 • 2023 Pediatric Rheumatology Symposium

    Thrombotic Microangiopathic Changes in Kidney Biopsies of Childhood-Onset Systemic Lupus Erythematous Patients with and Without Severe Hematologic Disturbances

    Cathy Tsin1, Megan Troxell1, Vivek Charu1, Rufei Lu2 and Joyce Hsu3, 1Stanford University, Palo Alto, CA, 2UCSF, San Francisco, CA, 3Stanford Medicine, Children's Health, Palo Alto, CA

    Background/Purpose: Outcomes for pediatric patients with lupus nephritis (LN) remain suboptimal. LN may present with thrombotic microangiopathy (TMA) seen on kidney biopsy. Childhood-onset SLE patients…
  • Abstract Number: 0099 • ACR Convergence 2022

    Impact of Multimodal Independent Medical Education on Improving Outcomes and Reducing Disparities in Systemic Lupus Erythematosus and Lupus Nephritis

    Lisa Handley1, Kimberly Lovin Nealy2 and Sarah A. Nisly3, 1Clinical Care Options, Clive, IA, 2Clinical Care Options, Matthews, NC, 3Clinical Care Options, Reston, VA

    Background/Purpose: Due to its range of manifestations and lack of specific findings, early diagnosis of SLE is often a challenge, and serious complications, including LN,…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology